AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04604002 — intervention group
Intervention type: DEVICE
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
Study NCT04604002 — intervention group
Intervention type: DEVICE
Intervention: Color Fundus Photography
Description: Non-contact white light photography
Study NCT04604002 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: A non-contact test that uses light waves to take cross-sectional pictures of the retina
Study NCT03103243 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Group Sessions
Description: In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
Study NCT02975570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
Study NCT02975570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
Study NCT02975570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
Study NCT02975570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
Study NCT02975570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WHO MDR-TB regimen
Description: The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
Study NCT00811343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QFTB-G and T-SPOT.TB tests
Description: QFTB-G and T-SPOT.TB test before TST
Study NCT01881139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT01409148 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 124I-labeled monoclonal antibody Mu 11-1F4
Description: Single infusion of radiolabeled antibody: 2mCi (1 mg)
Study NCT00981890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
Study NCT00817180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Expiratory Pressure (PEP)
Description: Physiotherapy technique for airway clearance
Study NCT00817180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System
Description: Physiotherapy technique for airway clearance.
Study NCT04428879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Episcleral Plaque
Description: Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
Study NCT00924287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin
Description: 720,000 IU/kg every 8 hours for a maximum of 15 doses
Study NCT00924287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
Study NCT00924287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT00924287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
Study NCT00113880 — intervention group
Intervention type: BIOLOGICAL
Intervention: FluMist
Description: Nasal Sprayer dose of FluMist with annual follow up
Study NCT03676426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web platform for advance care planning/advance directive
Description: Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
Study NCT03676426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard advance directive
Description: Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
Study NCT02145221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Study NCT02297568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calciferol
Description: Comparison 25OHD levels between calciferol and placebo
Study NCT02297568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00997087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: Sublingual daily
Study NCT00997087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flumazenil
Description: Sublingual daily
Study NCT01785303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
Study NCT01785303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
Study NCT01785303 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CPAP
Description: CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
Study NCT01273233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus Type 71 Vaccine
Description: A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Study NCT01273233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Study NCT00240487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
Study NCT00240487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
Study NCT03105674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-drug local anesthetics (Combination)
Description: 1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml
Study NCT03105674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard local anesthetics (Combination)
Description: Marcaine and Lidocaine
Study NCT00291148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Study NCT00291148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Study NCT04529668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D supplementation
Description: vitamin D supplementation
Study NCT04529668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual therapy for nasal polyposis
Description: steroids ( systemic and local )
Study NCT01760239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
Study NCT04125368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Facility Interventions
Description: 1. Intensified counselling on dietary diversity and increased meal frequency during pregnancy.~2. Strengthened government distribution of IFA supplies with counseling about its importance, managing side effects, and reminder about subsequent supplies.~3. Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~4. Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding.
Study NCT04125368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Interventions
Description: 1. Home visits to pregnant women by HEWs to discuss maternal nutrition (dietary diversity, adequate food intake, IFA supplementation, and weight gain), early breastfeeding practices, provide ANC and Pregnant Women Conference referrals, and engage husbands.~2. HEWs use A\&T intervention tools (e.g. posters and maternal nutrition follow-up card) at Pregnant Women Conferences/ Mother Support Groups to reinforce maternal nutrition messages, encourage ANC attendance, distribute IFA tablets, measure and track weight gain, promote early breastfeeding practices, and encourage husband participation.~3. HEWs and community volunteers (Women's Development Army (WDA), imams, etc.) deliver maternal nutrition messages and encourage ANC visits at kebele and community meetings.
Study NCT04125368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System Interventions
Description: 1. Trainings on the maternal nutrition interventions for health center heads, nurse-midwives, HEWs, community volunteers (WDA, imams, etc.), woreda health officers, and other key actors.~2. Supportive supervision of maternal nutrition activities conducted by woreda nutrition officers, woreda health officers, TDA or A\&T.
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or intraventricularly
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02481310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or intraventricularly
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02481310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02275260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Diffusion-Weighted Magnetic Resonance Imaging
Description: Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
Study NCT02275260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography
Description: Patients undergo a Transesophageal Echocardiography prior to the ablation itself
Study NCT02275260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paperbased neurocognitive testing
Description: To assess the impact of PVI on the patient's neurocognitive status
Study NCT03131414 — intervention group
Intervention type: OTHER
Intervention: Diet
Description: Dietary intake
Study NCT03131414 — intervention group
Intervention type: OTHER
Intervention: Gastrointestinal microbiome
Description: Genomic sequencing of stool for gut bacteria
Study NCT01609699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Contour I-Y system
Description: The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
Study NCT05321238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High agency and immediate threat
Description: Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
Study NCT05321238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High agency and distant threat
Description: Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
Study NCT05321238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low agency and immediate threat
Description: Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
Study NCT05321238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low agency and distant threat
Description: Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
Study NCT03675165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Possible Self
Description: A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT or intraventricularly
Study NCT02481310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02479568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
Study NCT02479568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Florida OJ
Description: 500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
Study NCT02479568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Florida OJ-enriched
Description: 500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
Study NCT02063334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
Study NCT02063334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04244890 — intervention group
Intervention type: DEVICE
Intervention: Uninterrupted CPAP for the first hours of life
Description: Directly at birth the infant will be supported with PPV with PEEP as needed, followed by nasal CPAP. Support will be provided with a single device for up to four hours.
Study NCT01621698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early paravertebral block
Description: In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
Study NCT01621698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Paravertebral block.
Description: In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
Study NCT02577666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecologically Based Therapy
Description: 6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
Study NCT02577666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing Only
Description: receives 3 months of project supported rental assistance
Study NCT02577666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: receives services as normally offered within the community
Study NCT02577666 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: receives services as normally offered within the community
Study NCT02126501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual pressure wean
Description: NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
Study NCT02885987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmplifEYE
Description: AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Description: At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
Study NCT04025151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol brief intervention
Description: At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes